Steadman Philippon Research Institute, Vail, Colorado, USA.
Clinic for Trauma and Orthopaedic Surgery, BG Trauma Center Ludwigshafen, University of Heidelberg, Ludwigshafen, Germany.
Am J Sports Med. 2021 Jun;49(7):1839-1846. doi: 10.1177/03635465211006479. Epub 2021 Apr 29.
When comprehensive arthroscopic management (CAM) for glenohumeral osteoarthritis fails, total shoulder arthroplasty (TSA) may be needed, and it remains unknown whether previous CAM adversely affects outcomes after subsequent TSA.
To compare the outcomes of patients with glenohumeral osteoarthritis who underwent TSA as a primary procedure with those who underwent TSA after CAM (CAM-TSA).
Cohort study; Level of evidence, 3.
Patients younger than 70 years who underwent primary TSA or CAM-TSA and were at least 2 years postoperative were included. A total of 21 patients who underwent CAM-TSA were matched to 42 patients who underwent primary TSA by age, sex, and grade of osteoarthritis. Intraoperative blood loss and surgical time were assessed. Patient-reported outcome (PRO) scores were collected preoperatively and at final follow-up including the American Shoulder and Elbow Surgeons (ASES) score, Single Assessment Numeric Evaluation (SANE), shortened version of Disabilities of the Arm, Shoulder and Hand (QuickDASH), 12-Item Short Form Health Survey Physical Component Summary (SF-12 PCS), visual analog scale, and patient satisfaction. Revision arthroplasty was defined as failure.
Of 63 patients, 56 of them (19 CAM-TSA and 37 primary TSA; 88.9%) were available for follow-up. There were 16 female (28.6%) and 40 male (71.4%) patients with a mean age of 57.8 years (range, 38.8-66.7 years). There were no significant differences in intraoperative blood loss ( > .999) or surgical time ( = .127) between the groups. There were 4 patients (7.1%) who had failure, and failure rates did not differ significantly between the CAM-TSA (5.3%; n = 1) and primary TSA (8.1%; n = 3) groups ( > .999). Additionally, 2 patients underwent revision arthroplasty because of trauma. A total of 50 patients who did not experience failure (17 CAM-TSA and 33 primary TSA) completed PRO measures at a mean follow-up of 4.8 years (range, 2.0-11.5 years), with no significant difference between the CAM-TSA (4.4 years [range, 2.1-10.5 years]) and primary TSA (5.0 years [range, 2.0-11.5 years]) groups ( = .164). Both groups improved significantly from preoperatively to postoperatively in all PRO scores ( < .05). No significant differences in any median PRO scores between the CAM-TSA and primary TSA groups, respectively, were seen at final follow-up: ASES: 89.9 (interquartile range [IQR], 74.9-96.6) versus 94.1 (IQR, 74.9-98.3) ( = .545); SANE: 84.0 (IQR, 74.0-94.0) versus 91.5 (IQR, 75.3-99.0) ( = .246); QuickDASH: 9.0 (IQR, 3.4-27.3) versus 9.0 (IQR, 5.1-18.1) ( = .921); SF-12 PCS: 53.8 (IQR, 50.1-57.1) versus 49.3 (IQR, 41.2-56.5) ( = .065); and patient satisfaction: 9.5 (IQR, 7.3-10.0) versus 9.0 (IQR, 5.3-10.0) ( = .308).
Patients with severe glenohumeral osteoarthritis who failed previous CAM benefited similarly from TSA compared with patients who opted directly for TSA.
当全关节镜下处理(CAM)治疗肩关节炎失败时,可能需要进行全肩关节置换术(TSA),目前尚不清楚先前的 CAM 是否会对随后的 TSA 后的结果产生不利影响。
比较初次行 TSA 与 CAM 后继行 TSA(CAM-TSA)的肩关节炎患者的结局。
队列研究;证据等级,3 级。
纳入年龄小于 70 岁、接受初次 TSA 或 CAM-TSA 且术后至少 2 年的患者。共纳入 21 例 CAM-TSA 患者,根据年龄、性别和骨关节炎分级与 42 例初次 TSA 患者匹配。评估术中失血量和手术时间。收集术前和末次随访时的患者报告结局(PRO)评分,包括美国肩肘外科医师协会(ASES)评分、单项评估数值评估(SANE)、简化版的上肢残疾问卷(QuickDASH)、12 项简明健康调查量表躯体成分摘要(SF-12 PCS)、视觉模拟评分和患者满意度。翻修关节置换术定义为失败。
63 例患者中,56 例(19 例 CAM-TSA 和 37 例初次 TSA;88.9%)获得随访。其中 16 例为女性(28.6%),40 例为男性(71.4%),平均年龄为 57.8 岁(范围,38.8-66.7 岁)。两组间术中失血量( >.999)或手术时间( =.127)差异均无统计学意义。4 例(7.1%)患者发生失败,CAM-TSA(5.3%;n=1)和初次 TSA(8.1%;n=3)组间失败率差异无统计学意义( >.999)。此外,2 例患者因创伤而行翻修关节置换术。50 例未发生失败的患者(17 例 CAM-TSA 和 33 例初次 TSA)完成了 PRO 测量,平均随访时间为 4.8 年(范围,2.0-11.5 年),CAM-TSA 组(4.4 年[范围,2.1-10.5 年])和初次 TSA 组(5.0 年[范围,2.0-11.5 年])间差异无统计学意义( =.164)。两组患者在所有 PRO 评分上均较术前显著改善( <.05)。CAM-TSA 组和初次 TSA 组的最终随访时分别在以下中位 PRO 评分上差异均无统计学意义:ASES:89.9(四分位距[IQR],74.9-96.6)与 94.1(IQR,74.9-98.3)( =.545);SANE:84.0(IQR,74.0-94.0)与 91.5(IQR,75.3-99.0)( =.246);QuickDASH:9.0(IQR,3.4-27.3)与 9.0(IQR,5.1-18.1)( =.921);SF-12 PCS:53.8(IQR,50.1-57.1)与 49.3(IQR,41.2-56.5)( =.065);以及患者满意度:9.5(IQR,7.3-10.0)与 9.0(IQR,5.3-10.0)( =.308)。
先前 CAM 治疗失败的严重肩关节炎患者从 TSA 中获益与直接选择 TSA 的患者相似。